Peregrine Pharmaceuticals, Inc. (NASDAQ:PPHM) (NASDAQ:PPHMP), a
biopharmaceutical company focused on developing therapeutics to
stimulate the body's immune system to fight cancer, today announced
financial results for the second quarter of fiscal year (FY) 2016
ended October 31, 2015, and provided an update on its advancing
clinical pipeline and other corporate developments.
Highlights Since July 31, 2015
"I am pleased to report that we are nearing
completion of enrollment for our Phase III SUNRISE trial with over
90% of the intended number of patients enrolled. We have also
made substantial progress toward initiating several new trials
including a Phase II/III breast cancer study and a Phase II NSCLC
trial in combination with AstraZeneca’s anti-PD-L1 antibody,
durvalumab," said Steven W. King, president and chief executive
officer of Peregrine. “Our goal is to transition our leading
SUNRISE clinical sites into our new Phase II NSCLC trial which
should significantly expedite study start-up activities. We
are encouraged by the fact that a number of investigators from
hospitals that participated in the SUNRISE trial have already
enthusiastically agreed to participate in our upcoming NSCLC
trial.”
“As treatment paradigms shift to incorporate new
drugs, it is clear that both chemotherapy and immuno-oncology
agents will continue to be critical to patient care. Taken
together, we believe our SUNRISE trial, as well as the newly
planned breast and lung cancer trials will allow us to maximize the
potential of bavituximab in both settings,” said Joseph Shan, vice
president of clinical and regulatory affairs of Peregrine.
“We are committed to continuing to identify new potential
indications, patient populations and therapies that can benefit
from combination treatment with bavituximab. From what we
have seen to date in our preclinical and translational studies, the
opportunity appears vast, and we are hard at work converting the
most promising prospects into true value.”
Clinical Development
Highlights
- As of today, more than 90% of the planned number of patients
have been enrolled in the Phase III SUNRISE trial, representing a
sufficient number of patients required to trigger the two
pre-planned interim analyses as well as the final analysis for
trial unblinding. The company expects to reach the trial’s
estimated enrollment of 582 patients in the coming
weeks.
- Peregrine and AstraZeneca expanded their cancer immunotherapy
clinical trial collaboration to evaluate bavituximab in combination
with AstraZeneca’s investigational anti-PD-L1 immune checkpoint
inhibitor, durvalumab (MEDI4736). The companies are currently
planning a global Phase II study in patients with previously
treated squamous or non-squamous NSCLC, as well as a Phase I/Ib
trial that will evaluate the safety and efficacy of bavituximab in
combination with durvalumab and chemotherapy in multiple solid
tumors. The company expects the Phase II study to be
initiated in early 2016 with the Phase I/Ib study beginning later
in 2016.
- Peregrine continues to finalize plans for its Phase II/III
trial to evaluate bavituximab with chemotherapy combinations in
HER2-negative metastatic breast cancer. This trial is on track to
be initiated by the end of calendar year 2015.
Supportive Research
Highlights
- Positive results were presented at the 2015 annual meeting of
the Society for Immunotherapy of Cancer (SITC) from multiple new
preclinical studies demonstrating enhanced anti-tumor activity and
immune activation for combinations of a preclinical bavituximab
equivalent and checkpoint inhibitors such as anti-PD-1 and
anti-CTLA-4 in preclinical models of breast cancer and
melanoma. Additionally, the company announced preliminary
results for a new clinical test specifically designed to illustrate
how bavituximab modulates immune responses in the tumor
microenvironment.
- New data presented at the International Association for the
Study of Lung Cancer's (IASLC's) World Conference on Lung Cancer
(WCLC) from a translational study of bavituximab demonstrated the
ability of bavituximab, alone or in combination with docetaxel, to
induce signs of immune activation in non-small cell lung cancer
(NSCLC) patient-derived tumor samples, particularly when there was
negative PD-L1 expression in the tumor sample. These data
further support the potential mechanistic synergies for bavituximab
with chemotherapy and checkpoint inhibitors targeting the
PD-1/PD-L1 pathway.
- Summary data presented at the Combination Immunotherapy
Strategies session at the 10th Annual Immunotherapy and Vaccine
Summit (ImVacS), highlighted key findings from several recent
bavituximab-focused studies including: the potential of bavituximab
to shift the tumor microenvironment from immuno-suppressive in
which tumors evade immune detection to a state of immune activation
in which the immune system recognizes and fights the tumor;
bavituximab's potential to increase the number of activated CD8+
cells in the tumor, which stimulates PD-1 expression, potentially
increasing the number of patients able to respond to PD-1 and PD-L1
targeting immunotherapies; and, results from several clinical and
preclinical studies in a range of tumor types showing that
bavituximab and bavituximab-like antibodies, in combination with
conventional therapy, have consistently demonstrated Kaplan-Meier
graphs that follow the classic immunotherapy survival plateau.
Corporate Highlights
- Peregrine closed a registered direct offering to a single
institutional investor raising $20 million dollars. The funds
raised from this financing will support the ongoing Phase III
SUNRISE trial, and newly planned later-stage company-sponsored
trials in breast cancer and NSCLC.
Avid Bioservices Highlights
“Our contract manufacturing business continues
to strengthen with a 52% current quarter increase in revenue
compared to the prior year period and year-to-date growth of 61%,”
stated Paul Lytle, chief financial officer of Peregrine. “Our
new state-of-the-art manufacturing facility is now ready for the
initial phase of GMP manufacturing and demand for Avid’s capacity
continues to grow with our current backlog now at $49
million. Given the revenue growth and committed backlog, we
are increasing our contract manufacturing revenue guidance to a
range of $35 to $40 million for the full-year 2016.”
- During the second quarter of FY 2016, Avid Bioservices
achieved record-breaking revenues generating approximately $9.5
million dollars, a 52% increase in revenue compared to the same
quarter in the prior year.
- Avid’s new manufacturing facility is now ready for the
initial phase of GMP manufacturing. The state-of-the-art
facility will accommodate single use bioreactors (SUBs) at up to
2,000 liter scale. Upcoming production runs will support late stage
clinical development as well as process validation activities in
anticipation of bavituximab and other client commercial product
needs. The facility has the capacity to potentially generate
approximately $40 million in new revenue annually.
- Contract manufacturing committed backlog reached $49
million from existing customers covering services to be completed
in FY 2016 and into FY 2017.
Financial Results
Total revenues for the second quarter of FY 2016
were $9,523,000, compared to $6,300,000 for the same quarter of the
prior fiscal year. The increase was attributed to an increase in
contract manufacturing revenue generated from Avid Bioservices.
Contract manufacturing revenue from Avid's
clinical and commercial biomanufacturing services provided to its
third-party clients for the second quarter FY 2016 were $9,523,000,
compared to $6,263,000 for the same quarter of the prior fiscal
year. Peregrine expects third-party contract manufacturing revenue
for the entire fiscal year to be between $35 million and $40
million, compared to previous guidance of $30 million to $35
million during last quarter’s earnings call. In addition to
providing biomanufacturing services to its third-party clients,
Avid will continue to support the clinical development and
potential commercialization of bavituximab.
Total costs and expenses in the second quarter
of FY 2016 were $23,347,000, compared to $18,437,000 in the second
quarter of FY 2015. This increase was primarily attributable to
current quarter increases in research and development expenses
associated with the SUNRISE Phase III trial, newly planned
later-stage company-sponsored trials in breast cancer and NSCLC,
and an increase in the cost of contract manufacturing associated
with higher reported revenue. For the second quarter of FY 2016,
research and development expenses were $14,190,000, compared to
$10,003,000 for the second quarter of FY 2015. For the second
quarter of FY 2016, cost of contract manufacturing was $4,741,000,
compared to $4,139,000 for the second quarter of FY 2015.
Peregrine's consolidated net loss attributable
to common stockholders was $14,578,000, or $0.07 per share, for the
second quarter of FY 2016, compared to a net loss attributable to
common stockholders of $13,131,000, or $0.07 per share, for the
same prior year quarter.
Peregrine reported $72,005,000 in cash and cash
equivalents as of October 31, 2015 compared to $68,001,000 at
fiscal year ended April 30, 2015.
More detailed financial information and analysis
may be found in Peregrine's Quarterly Report on Form 10-Q, which
will be filed with the Securities and Exchange Commission
today.
Conference Call
Peregrine will host a conference call and
webcast this afternoon, December 10, 2015, at 4:30 PM ET (1:30 PM
PT).
To listen to the conference call, please dial
(877) 312-5443 or (253) 237-1126 and request the Peregrine
Pharmaceuticals conference call. To listen to the live webcast, or
access the archived webcast, please visit:
http://ir.peregrineinc.com/events.cfm.
About Peregrine Pharmaceuticals, Inc.
Peregrine Pharmaceuticals, Inc. is a
biopharmaceutical company with a pipeline of novel drug candidates
in clinical trials focused on the treatment of cancer. The
company's lead immunotherapy candidate, bavituximab, is in Phase
III development for the treatment of previously treated non-small
cell lung cancer (the "SUNRISE trial") along with several
investigator-sponsored trials evaluating other treatment
combinations and additional oncology indications. Peregrine
also has in-house cGMP manufacturing capabilities through its
wholly-owned subsidiary Avid Bioservices, Inc. (www.avidbio.com),
which provides development and biomanufacturing services for both
Peregrine and third-party customers. For more information, please
visit www.peregrineinc.com.
Safe Harbor Statement:
Statements in this press release which are not purely historical,
including statements regarding Peregrine Pharmaceuticals'
intentions, hopes, beliefs, expectations, representations,
projections, plans or predictions of the future are forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995. The forward-looking statements involve risks
and uncertainties including, but not limited to, the risk that the
company may experience delays in the enrollment of patients in the
Phase III SUNRISE trial and that the Phase III SUNRISE trial may
not achieve its anticipated enrollment timeline, the risk that the
results from the Phase III SUNRISE trial may not support a future
Biologics License Application (BLA) submission, the risk that
readouts and interim data expected from new clinical trials may not
occur within the time frames anticipated, the risk that the company
may not have or raise adequate financial resources to complete all
of its contemplated clinical trials, the risk that the company may
experience delays in initiating its contemplated clinical trials,
the risk that data from pre-clinical and translational studies and
early stage clinical trials, including ISTs, may not correlate with
the results of later stage clinical trials, the risk that Avid's
revenue growth may slow or decline, the risk that Avid may
experience technical difficulties in processing customer orders
which could delay delivery of products to customers and receipt of
payment, and the risk that one or more existing Avid customers
terminates its contract prior to completion. The company's actual
results could differ materially from those in any such
forward-looking statements. Factors that could cause actual results
to differ materially include, but are not limited to, uncertainties
associated with completing preclinical and clinical trials for our
technologies; the early stage of product development; the
significant costs to develop our products as all of our products
are currently in development, preclinical studies or clinical
trials; obtaining additional financing to support our operations
and the development of our products; obtaining regulatory approval
for our technologies; anticipated timing of regulatory filings and
the potential success in gaining regulatory approval and complying
with governmental regulations applicable to our business. Our
business could be affected by a number of other factors, including
the risk factors listed from time to time in our reports filed with
the Securities and Exchange Commission including, but not limited
to, our annual report on Form 10-K for the fiscal year ended April
30, 2015 as well as any updates to these risk factors filed from
time to time in the company's other filings with the Securities and
Exchange Commission. The company cautions investors not to place
undue reliance on the forward-looking statements contained in this
press release. Peregrine Pharmaceuticals, Inc. disclaims any
obligation, and does not undertake to update or revise any
forward-looking statements in this press release.
|
PEREGRINE PHARMACEUTICALS, INC. |
|
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND
COMPREHENSIVE LOSS (UNAUDITED) |
(UNAUDITED) |
|
|
THREE MONTHS
ENDEDOCTOBER 31, |
|
SIX MONTHS
ENDEDOCTOBER 31, |
|
|
2015 |
|
|
|
2014 |
|
|
|
2015 |
|
|
|
2014 |
|
|
|
|
|
|
|
|
|
REVENUES: |
|
|
|
|
|
|
|
Contract manufacturing
revenue |
$ |
9,523,000 |
|
|
$ |
6,263,000 |
|
|
$ |
18,902,000 |
|
|
$ |
11,759,000 |
|
License revenue |
|
- |
|
|
|
37,000 |
|
|
|
292,000 |
|
|
|
37,000 |
|
Total
revenues |
|
9,523,000 |
|
|
|
6,300,000 |
|
|
|
19,194,000 |
|
|
|
11,796,000 |
|
|
|
|
|
|
|
|
|
COSTS AND
EXPENSES: |
|
|
|
|
|
|
|
Cost of contract
manufacturing |
|
4,741,000 |
|
|
|
4,139,000 |
|
|
|
9,349,000 |
|
|
|
7,722,000 |
|
Research and
development |
|
14,190,000 |
|
|
|
10,003,000 |
|
|
|
28,108,000 |
|
|
|
20,204,000 |
|
Selling, general and
administrative |
|
4,416,000 |
|
|
|
4,295,000 |
|
|
|
9,315,000 |
|
|
|
9,178,000 |
|
Total costs
and expenses |
|
23,347,000 |
|
|
|
18,437,000 |
|
|
|
46,772,000 |
|
|
|
37,104,000 |
|
|
|
|
|
|
|
|
|
LOSS FROM
OPERATIONS |
|
(13,824,000 |
) |
|
|
(12,137,000 |
) |
|
|
(27,578,000 |
) |
|
|
(25,308,000 |
) |
|
|
|
|
|
|
|
|
Interest and other
income |
|
626,000 |
|
|
|
37,000 |
|
|
|
657,000 |
|
|
|
79,000 |
|
|
|
|
|
|
|
|
|
NET
LOSS |
$ |
(13,198,000 |
) |
|
$ |
(12,100,000 |
) |
|
$ |
(26,921,000 |
) |
|
$ |
(25,229,000 |
) |
|
|
|
|
|
|
|
|
COMPREHENSIVE
LOSS |
$ |
(13,198,000 |
) |
|
$ |
(12,100,000 |
) |
|
$ |
(26,921,000 |
) |
|
$ |
(25,229,000 |
) |
|
|
|
|
|
|
|
|
Series E preferred stock
accumulated dividends |
|
(1,380,000 |
) |
|
|
(1,031,000 |
) |
|
|
(2,413,000 |
) |
|
|
(1,802,000 |
) |
|
|
|
|
|
|
|
|
Net loss
attributable to common stockholders |
$ |
(14,578,000 |
) |
|
$ |
(13,131,000 |
) |
|
$ |
(29,334,000 |
) |
|
$ |
(27,031,000 |
) |
|
|
|
|
|
|
|
|
WEIGHTED AVERAGE COMMON
SHARES OUTSTANDING: |
|
|
|
|
|
|
|
Basic and
Diluted |
|
203,942,411 |
|
|
|
179,962,275 |
|
|
|
200,629,892 |
|
|
|
179,540,265 |
|
|
|
|
|
|
|
|
|
BASIC AND DILUTED LOSS PER
COMMON SHARE |
$ |
(0.07 |
) |
|
$ |
(0. 07 |
) |
|
$ |
(0.15 |
) |
|
$ |
(0.15 |
) |
|
|
|
|
|
|
|
|
|
PEREGRINE PHARMACEUTICALS, INC. |
|
CONDENSED CONSOLIDATED BALANCE
SHEETS |
|
|
OCTOBER 31,2015 |
|
APRIL 30,2015 |
|
Unaudited |
|
|
ASSETS |
|
|
|
CURRENT ASSETS: |
|
|
|
Cash and cash
equivalents |
$ |
72,005,000 |
|
|
$ |
68,001,000 |
|
Trade and other
receivables, net |
|
2,904,000 |
|
|
|
3,813,000 |
|
Inventories |
|
12,554,000 |
|
|
|
7,354,000 |
|
Prepaid expenses and other
current assets, net |
|
1,995,000 |
|
|
|
1,355,000 |
|
Total
current assets |
|
89,458,000 |
|
|
|
80,523,000 |
|
Property and equipment,
net |
|
21,764,000 |
|
|
|
15,124,000 |
|
Other assets |
|
1,435,000 |
|
|
|
1,817,000 |
|
TOTAL ASSETS |
$ |
112,657,000 |
|
|
$ |
97,464,000 |
|
LIABILITIES AND
STOCKHOLDERS’ EQUITY |
|
|
|
CURRENT LIABILITIES: |
|
|
|
Accounts payable |
$ |
6,901,000 |
|
|
$ |
10,385,000 |
|
Accrued clinical trial and
related fees |
|
6,138,000 |
|
|
|
3,910,000 |
|
Accrued payroll and
related costs |
|
4,130,000 |
|
|
|
4,606,000 |
|
Deferred revenue |
|
9,688,000 |
|
|
|
6,630,000 |
|
Customer deposits |
|
14,935,000 |
|
|
|
11,363,000 |
|
Other current
liabilities |
|
667,000 |
|
|
|
437,000 |
|
Total
current liabilities |
|
42,459,000 |
|
|
|
37,331,000 |
|
|
|
|
|
Deferred rent, less
current portion |
|
972,000 |
|
|
|
1,098,000 |
|
Commitments and
contingencies |
|
|
|
|
|
|
|
STOCKHOLDERS’ EQUITY: |
|
|
|
Preferred stock – $0.001
par value; authorized 5,000,000 shares; issued and outstanding –
1,577,440 and 1,574,764, respectively |
|
2,000 |
|
|
|
2,000 |
|
Common stock – $0.001 par
value; authorized 500,000,000 shares; outstanding – 225,824,551 and
193,346,627, respectively |
|
226,000 |
|
|
|
193,000 |
|
Additional paid-in
capital |
|
549,543,000 |
|
|
|
512,464,000 |
|
Accumulated deficit |
|
(480,545,000 |
) |
|
|
(453,624,000 |
) |
Total
stockholders’ equity |
|
69,226,000 |
|
|
|
59,035,000 |
|
TOTAL LIABILITIES AND
STOCKHOLDERS’ EQUITY |
$ |
112,657,000 |
|
|
$ |
97,464,000 |
|
|
|
|
|
|
|
|
|
Contacts:
Jay Carlson
Peregrine Pharmaceuticals, Inc.
(800) 987-8256
info@peregrineinc.com
Stephanie Diaz (Investors)
Vida Strategic Partners
415-675-7401
sdiaz@vidasp.com
Tim Brons (Media)
Vida Strategic Partners
415-675-7402
tbrons@vidasp.com
Avid Bioservices (NASDAQ:CDMO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Avid Bioservices (NASDAQ:CDMO)
Historical Stock Chart
From Apr 2023 to Apr 2024